Halt-MS logo High-dose immunosuppression and autologous bone marrow transplantation for MS

Information for
Could you be eligible?
Could you be
Locate a clinical site
Locate a
Clinical site



Information for Physicians
Information for

Halt-MS is sponsored by the
National Institute of Allergy
and Infectious Diseases
(a part
of the National Institutes of
Health) and is being conducted
by the Immune Tolerance

Terms of Use | Privacy policy

© 2007-9, Immune Tolerance Network

Information for Physicians

HALT-MS is an NIH-sponsored clinical trial evaluating autologous stem cell transplantation for poor prognosis MS.

Study Protocol

Peripheral blood stem cells (CD34+) are mobilized with G-CSF and prednisone, and collected.

Between 7-14 days later, participants are treated with a intensive conditioning regimen of BEAM (carmustine, etoposide, cytosine arabinoside and melphalan) + Thymoglobulin. The BEAM protocol followed by CD34-selected stem cell transplantation. Participants will remain hospitalized until the recovery of peripheral blood cell counts.

In a recently published Italian study, 18 of 19 patients with high disease activity and sustained clinical deterioration showed clinical stabilization or improvement following BEAM/rATG and autologous HCT [1].


The study is open to individuals 18-60 years of age, who:

Patients with primary progressive MS or secondary progressive MS without relapses for 12 or more months are not eligible. Patients must not have HIV, active hepatitis B or C infection or cirrhosis to be eligible.

*** ENROLLMENT IN the Halt-MS Study is NOW CLOSED ***

Adobe .pdf (93 kb)

* requires Adobe Acrobat Reader. Get it here.

[1] Saccardi, R. et al., Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood, 2005. 105(6): p. 2601-7